Commiphora molmol myrrh resin extracts, which have different physical properties such as polarity and dielectric constant, were prepared by immersion in extraction solvents (hot water, DMSO, hexane, ethanol, and methanol). Methanolic myrrh resin extracts showed broad antibacterial activity against isolated airborne bacteria. Furanoeudesma-1,3-diene and curzerene, as the main terpenoids in the methanolic myrrh resin extract, were analyzed using GC-MS, and the methanolic myrrh resin extracts were found to have antiviral activity (81.2% viral RNA inhibition) against H1N1 influenza virus. Biochars (wood powder-and rice husk-derived) coated with myrrh resin extracts also showed antiviral activity (22.6% and 24.3% viral RNA inhibition), due to the adsorption of terpenoids onto biochar. Myrrh resin extract using methanol as the extraction solvent is a promising agent with antibacterial and antiviral efficacy, and it can be utilized as a novel material via adsorption onto biochar for air filtration processes, cosmetics, fertilizers, drug delivery, and corrosion inhibition.

The first appearance of viruses can date back to the late last century. As an effective form of malware, viruses reside in the permanent storage of target hosts. Before a virus can execute, that must load into memory from the persistent storage included in the associated file. Due to the reliable destructive power of viruses, many mechanisms have been developed to defend computer systems against these hazardous threats. Antivirus software is one of the most famous and popular among these mechanisms. Most antivirus software uses static analysis (signature-based) technology on files stored in permanent storage, such as hard disks or USB flashes, to detect viruses hidden in files. Fileless malware was developed to enhance the survivability of malware by circumventing detection. Fileless malware only exists in the target hosts’ memory, not files. Antivirus software cannot even access the fileless malware code, much less analyze it, since it may be performed in memory directly without needing to load it from a disk. As a result, it is difficult for an antivirus engine to defend a system against fileless malware attacks. This paper proposes a kernel-based solution called Check-on-Execution (CoE) to detect fileless malware on a Linux system. When a program is going to execute a piece of code in a writable and executable memory area of a process, CoE suspends the code execution first. Coe retrieves the code from memory, packs the code with an ELF header to create an ELF file, and uses VirusTotal to check the file to prevent a Linux system from executing fileless malware. Experimental results show that CoE noticeably enhances the ability of a Linux system to defend itself again fileless malware. CoE is also suitable for protecting a system from shell code injection attacks, such as buffer and heap overflow attacks. It is capable of handling even packed malware. But in this paper, we only focus on fileless malware.

Abstract Kidney transplant recipients, because of a weak immune response due to the assumption of immunosuppressant are exposed to the risk of COVID-19 infection. This fact realize the problem on how to treat the severe infection without carrying the risk of acute rejection due to the reduction of the immunosuppressive drugs. The best are the prophylactic measures to be taken before transplantation as vaccination. If the patient is already transplanted, three measures may be undertaken: Vaccination, use of monoclonal antibodies, use of therapeutic antiviral small molecules. Concerning vaccination is still debated which one is the best and how many doses should be given. The surge of new virus variant is the major problem and invites to find new active vaccines. In addition, not all the transplanted patients develop antibodies. The other measure is the use of monoclonal antibodies. They may be used as prophylaxis or in the early stage of the disease. Finally, the antiviral small molecules may be used again as prophylaxis or treatment. Their major drawback are the interference with the immunosuppressive drugs and the fact that some of them cannot be administered to patients with low eGFR.